{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:43:18Z","timestamp":1791614598990,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Addictive Behaviors"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.addbeh.2022.107283","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T11:08:40Z","timestamp":1645009720000},"page":"107283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["N-acetyl cysteine in the treatment of cannabis use disorder: A systematic review of clinical trials"],"prefix":"10.1016","volume":"129","author":[{"given":"Rishi","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Krishna","family":"Tikka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish Ramesh","family":"Bhute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binaya Kumar","family":"Bastia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.addbeh.2022.107283_b0005","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/14734220601142878","article-title":"N-acetylcysteine and neurodegenerative diseases: Basic and clinical pharmacology","volume":"6","author":"Arakawa","year":"2007","journal-title":"Cerebellum"},{"issue":"1","key":"10.1016\/j.addbeh.2022.107283_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-019-3628-5","article-title":"N-acetylcysteine for cessation of tobacco smoking: Rationale and study protocol for a randomised controlled trial","volume":"20","author":"Arancini","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.addbeh.2022.107283_b0015","series-title":"Revista Brasileira de Psiquiatria","first-page":"168","article-title":"Systematic review of N-acetylcysteine in the treatment of addictions","author":"Asevedo","year":"2014"},{"issue":"7","key":"10.1016\/j.addbeh.2022.107283_b0020","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nn1069","article-title":"Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse","volume":"6","author":"Baker","year":"2003","journal-title":"Nature Neuroscience"},{"issue":"3","key":"10.1016\/j.addbeh.2022.107283_b0025","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1046\/j.1471-4159.2001.00075.x","article-title":"Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function","volume":"76","author":"Barger","year":"2001","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.addbeh.2022.107283_b0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jsat.2015.12.003","article-title":"Low pretreatment impulsivity and high medication adherence increase the odds of abstinence in a trial of N-acetylcysteine in adolescents with cannabis use disorder","volume":"63","author":"Bentzley","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.addbeh.2022.107283_b0035","series-title":"Trends in Pharmacological Sciences","first-page":"167","article-title":"The promise of N-acetylcysteine in neuropsychiatry","author":"Berk","year":"2013"},{"key":"10.1016\/j.addbeh.2022.107283_b0040","series-title":"Addiction science & clinical practice","first-page":"4","article-title":"Marijuana dependence and its treatment","author":"Budney","year":"2007"},{"key":"10.1016\/j.addbeh.2022.107283_b0045","unstructured":"CEBM, U. of O. (2009). Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009) \u2014 Centre for Evidence-Based Medicine (CEBM), University of Oxford. CEBM. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009."},{"issue":"4","key":"10.1016\/j.addbeh.2022.107283_b0050","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/0004867412474074","article-title":"Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo","volume":"47","author":"Das","year":"2013","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1016\/j.addbeh.2022.107283_b0055","series-title":"Journal of Psychiatry and Neuroscience","first-page":"78","article-title":"N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action","author":"Dean","year":"2011"},{"key":"10.1016\/j.addbeh.2022.107283_b0060","series-title":"Neuroscience and Biobehavioral Reviews","first-page":"294","article-title":"Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review","author":"Deepmala","year":"2015"},{"issue":"12","key":"10.1016\/j.addbeh.2022.107283_b0065","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","article-title":"The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"5","author":"Degenhardt","year":"2018","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.addbeh.2022.107283_b0070","series-title":"American Journal on Addictions","first-page":"660","article-title":"N-acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis","author":"Duailibi","year":"2017"},{"issue":"8","key":"10.1016\/j.addbeh.2022.107283_b0075","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1176\/appi.ajp.2012.12010055","article-title":"A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents","volume":"169","author":"Gray","year":"2012","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.addbeh.2022.107283_b0080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.drugalcdep.2017.04.020","article-title":"A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults","volume":"177","author":"Gray","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"7829","key":"10.1016\/j.addbeh.2022.107283_b0085","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Online)"},{"issue":"4","key":"10.1016\/j.addbeh.2022.107283_b0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/WNF.0b013e31829ae713","article-title":"N-acetylcysteine boosts brain and blood glutathione in gaucher and Parkinson diseases","volume":"36","author":"Holmay","year":"2013","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/j.addbeh.2022.107283_b0095","doi-asserted-by":"crossref","unstructured":"Jimmy, B., & Jose, J. (2011). Patient medication adherence: Measures in daily practice. In Oman Medical Journal (Vol. 26, Issue 3, pp. 155\u2013159). Oman Med J. doi:10.5001\/omj.2011.38.","DOI":"10.5001\/omj.2011.38"},{"issue":"3","key":"10.1016\/j.addbeh.2022.107283_b0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.31887\/DCNS.2017.19.3\/glafaye","article-title":"Cannabis, cannabinoids, and health","volume":"19","author":"Lafaye","year":"2017","journal-title":"Dialogues in Clinical Neuroscience"},{"issue":"12","key":"10.1016\/j.addbeh.2022.107283_b0105","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1523\/JNEUROSCI.5129-07.2008","article-title":"Glutamate release in the nucleus accumbens core is necessary for heroin seeking","volume":"28","author":"LaLumiere","year":"2008","journal-title":"Journal of Neuroscience"},{"issue":"5","key":"10.1016\/j.addbeh.2022.107283_b0110","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1521-0391.2013.12034.x","article-title":"A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence","volume":"22","author":"LaRowe","year":"2013","journal-title":"American Journal on Addictions"},{"key":"10.1016\/j.addbeh.2022.107283_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1016\/j.addbeh.2022.107283_b0120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.pnpbp.2006.10.001","article-title":"An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: A pilot study","volume":"31","author":"Mardikian","year":"2007","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.addbeh.2022.107283_b0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.drugalcdep.2018.07.018","article-title":"Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study","volume":"192","author":"McClure","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.addbeh.2022.107283_b0130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40263-014-0142-x","article-title":"Potential role of N-acetylcysteine in the management of substance use disorders","volume":"28","author":"McClure","year":"2014","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.addbeh.2022.107283_b0135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cct.2014.08.011","article-title":"Achieving cannabis cessation - Evaluating N-acetylcysteine treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the national institute on drug abuse clinical trials network","volume":"39","author":"McClure","year":"2014","journal-title":"Contemporary Clinical Trials"},{"issue":"8","key":"10.1016\/j.addbeh.2022.107283_b0140","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1523\/JNEUROSCI.23-08-03531.2003","article-title":"Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior","volume":"23","author":"McFarland","year":"2003","journal-title":"Journal of Neuroscience"},{"issue":"1","key":"10.1016\/j.addbeh.2022.107283_b0145","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3450-0","article-title":"A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine (\u201cice\u201d) dependence","volume":"20","author":"McKetin","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.addbeh.2022.107283_b0150","series-title":"Expert Opinion on Drug Metabolism and Toxicology","first-page":"279","article-title":"N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects","author":"Minarini","year":"2017"},{"key":"10.1016\/j.addbeh.2022.107283_b0155","doi-asserted-by":"crossref","unstructured":"Morley, K. C., Baillie, A., Van Den Brink, W., Chitty, K. E., Brady, K., Back, S. E., \u2026 Haber, P. S. (2018). N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. In Expert Opinion on Investigational Drugs (Vol. 27, Issue 8, pp. 667\u2013675). Expert Opin Investig Drugs. doi:10.1080\/13543784.2018.1501471.","DOI":"10.1080\/13543784.2018.1501471"},{"issue":"1","key":"10.1016\/j.addbeh.2022.107283_b0160","first-page":"28","article-title":"The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: A double-blind controlled, crossover study","volume":"18","author":"Mousavi","year":"2015","journal-title":"Archives of Iranian Medicine"},{"key":"10.1016\/j.addbeh.2022.107283_b0165","series-title":"Psychiatry Research","first-page":"197","article-title":"N-acetylcysteine for treating cocaine addiction \u2013 A systematic review","author":"Nocito Echevarria","year":"2017"},{"key":"10.1016\/j.addbeh.2022.107283_b0170","series-title":"Pharmacology Biochemistry and Behavior","first-page":"801","article-title":"Glutamatergic medications for the treatment of drug and behavioral addictions","author":"Olive","year":"2012"},{"issue":"5","key":"10.1016\/j.addbeh.2022.107283_b0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1179\/1351000215Y.0000000004","article-title":"N-acetylcysteine for therapy-resistant tobacco use disorder: A pilot study","volume":"20","author":"Prado","year":"2015","journal-title":"Redox Report"},{"key":"10.1016\/j.addbeh.2022.107283_b0180","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fnbeh.2020.00122","article-title":"N-Acetylcysteine and Acetylsalicylic Acid Inhibit Alcohol Consumption by Different Mechanisms: Combined Protection","volume":"14","author":"Quintanilla","year":"2020","journal-title":"Frontiers in Behavioral Neuroscience"},{"key":"10.1016\/j.addbeh.2022.107283_b0185","series-title":"Sports Medicine","first-page":"1619","article-title":"Performance and Side Effects of Supplementation with N-Acetylcysteine: A Systematic Review and Meta-Analysis","author":"Rhodes","year":"2017"},{"issue":"Issue 3","key":"10.1016\/j.addbeh.2022.107283_b0190","article-title":"The well-built clinical question: A key to evidence-based decisions","volume":"123","author":"Richardson","year":"1995","journal-title":"ACP Journal Club"},{"issue":"6","key":"10.1016\/j.addbeh.2022.107283_b0195","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2174\/1871527314666150529144655","article-title":"Glutamate transporter GLT-1 as a therapeutic target for substance use disorders","volume":"14","author":"Roberts-Wolfe","year":"2015","journal-title":"CNS & Neurological Disorders - Drug Targets"},{"issue":"3","key":"10.1016\/j.addbeh.2022.107283_b0200","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.addbeh.2012.11.003","article-title":"Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial","volume":"38","author":"Roten","year":"2013","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.addbeh.2022.107283_b0205","doi-asserted-by":"crossref","unstructured":"Samuni, Y., Goldstein, S., Dean, O. M., & Berk, M. (2013). The chemistry and biological activities of N-acetylcysteine. In Biochimica et Biophysica Acta - General Subjects (Vol. 1830, Issue 8, pp. 4117\u20134129). Biochim Biophys Acta. doi:10.1016\/j.bbagen.2013.04.016.","DOI":"10.1016\/j.bbagen.2013.04.016"},{"issue":"1\u20133","key":"10.1016\/j.addbeh.2022.107283_b0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1385\/MN:24:1-3:107","article-title":"Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death","volume":"24","author":"Sattler","year":"2001","journal-title":"Molecular Neurobiology"},{"issue":"4","key":"10.1016\/j.addbeh.2022.107283_b0215","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000327682","article-title":"Efficacy of N-acetylcysteine in the treatment of nicotine dependence: A double-blind placebo-controlled pilot study","volume":"17","author":"Schmaal","year":"2011","journal-title":"European Addiction Research"},{"issue":"9","key":"10.1016\/j.addbeh.2022.107283_b0220","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1038\/npp.2012.66","article-title":"N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: A randomized crossover magnetic resonance spectroscopy study","volume":"37","author":"Schmaal","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.addbeh.2022.107283_b0225","doi-asserted-by":"crossref","first-page":"584","DOI":"10.12659\/AJCR.891399","article-title":"Spice\/k2 synthetic marijuana-induced toxic hepatitis treated with n-acetylcysteine","volume":"15","author":"Sheikh","year":"2014","journal-title":"American Journal of Case Reports"},{"issue":"2","key":"10.1016\/j.addbeh.2022.107283_b0230","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/ajad.12503","article-title":"Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation\u2014evaluating N-acetylcysteine treatment (ACCENT) study","volume":"26","author":"Sherman","year":"2017","journal-title":"American Journal on Addictions"},{"issue":"2","key":"10.1016\/j.addbeh.2022.107283_b0235","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00213-019-05384-z","article-title":"Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder","volume":"237","author":"Tomko","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.addbeh.2022.107283_b0240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.addbeh.2018.05.014","article-title":"The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine","volume":"85","author":"Tomko","year":"2018","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.addbeh.2022.107283_b0245","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-981-10-5562-1_2","article-title":"Definition of substance and non-substance addiction","volume":"1010","author":"Zou","year":"2017","journal-title":"Advances in Experimental Medicine and Biology"}],"container-title":["Addictive Behaviors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460322000491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460322000491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T18:51:05Z","timestamp":1759690265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306460322000491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":49,"alternative-id":["S0306460322000491"],"URL":"https:\/\/doi.org\/10.1016\/j.addbeh.2022.107283","relation":{},"ISSN":["0306-4603"],"issn-type":[{"value":"0306-4603","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-acetyl cysteine in the treatment of cannabis use disorder: A systematic review of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Addictive Behaviors","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addbeh.2022.107283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107283"}}